Mojca Skoberne

Mojca is an entrepreneur in residence at GV. She focuses on building organizations and transformational therapies anchored in understanding the immune system-tissue interactions.

Before GV, Mojca worked at multiple startup companies focused on decoding the immune system to develop therapeutics and bring them to patients across disease areas. She was SVP and Head of Immunology and Early Development at Cogen, which merged with Torque Therapeutics to form Repertoire Immune Medicines, a clinical-stage company. At Repertoire, Mojca led the discovery and development of cell therapies in oncology and autoimmune diseases. Before Cogen, Mojca had leadership roles at Gritstone Oncology, where she developed neoantigen cancer vaccines and TCR-T therapies, and Genocea Biosciences, where she developed cancer and infectious disease vaccines.

Mojca has a B.S. in Molecular Biology from the University of Ljubljana in Slovenia. She split her thesis work between Heidelberg and Ljubljana Universities and earned a Ph.D. in Medical Sciences. She completed her postdoctoral training at Rockefeller University and at NYU.